Genitourinary Cancer News

News

Multidisciplinary Tumor Boards Essential for Patients With Renal Cell Carcinoma

03/11/2024

Allison Casey

A recent study found the use of multidisciplinary tumor board created the opportunity for shared decision making with patients when considering multiple treatment options and clinical trials.

A recent study found the use of...

03/11/2024

Oncology

Conference Coverage

Nivolumab Plus Ipilimumab Improved Survival, Response Compared to Sunitinib Among Patients With Advanced Clear Cell Renal Cell Carcinoma

01/31/2024

Stephanie Holland ;

Long-term follow-up data from the phase 3 CheckMate-214 trial demonstrated that nivolumab plus ipilimumab improved survival and response compared to sunitinib among patients with advanced renal cell carcinoma.

Long-term follow-up data from...

01/31/2024

Oncology

Conference Coverage

Cabozantinib Plus Atezolizumab Significantly Prolonged PFS in Metastatic Castration-Resistant Prostate Cancer

01/25/2024

Stephanie Holland ;

Results from the ongoing phase 3 CONTACT-2 trial demonstrated that cabozantinib plus atezolizumab significantly improved rPFS compared to abiraterone plus prednisone or enzalutamide among patients with metastatic castration-resistant prostate...

Results from the ongoing phase 3...

01/25/2024

Oncology

News

FDA Approves Belzutifan for Patients With Advanced Renal Cell Carcinoma

01/23/2024

Grace Taylor , MS, MA;

The FDA has granted approval to belzutifan for patients with advanced renal cell carcinoma after they have received a PD-1 or PD-L1 inhibitor and a VEGF-TKI.

The FDA has granted approval to...

01/23/2024

Journal of Clinical Pathways

News

FDA Approves Enfortumab Vedotin-Ejfv With Pembrolizumab for Patients With Locally Advanced or Metastatic Urothelial Cancer

01/10/2024

Grace Taylor , MS, MA;

The FDA has granted approval to enfortumab vedotin-ejfv with pembrolizumab for patients with locally advanced or metastatic urothelial cancer.

The FDA has granted approval to...

01/10/2024

Journal of Clinical Pathways

News

Study Analyzes Cabozantinib Plus Nivolumab and Ipilimumab for Patients With aRCC Who Have IMDC Intermediate or Poor Risk Scores

03/30/2023

Grace Taylor , MS, MA;

At the 2023 ASCO GU Cancers Symposium, Thomas Powles, MD, and colleagues presented an analysis of the phase 3 clinical trial COSMIC-313, which compared the use of cabozantinib (C) plus nivolumab (N) and ipilimumab (I) versus a placebo with N...

At the 2023 ASCO GU Cancers...

03/30/2023

Journal of Clinical Pathways

News

Real-World Outcomes of EBRT Treatment for Patients With Localized Prostate Cancer

03/03/2023

Grace Taylor , MS, MA;

At the 2023 ASCO GU Cancers Symposium, Lawrence Karsh, MD, and colleagues presented data on real-world outcomes for using external beam radiation therapy to treat patients with high-risk localized prostate cancer (LPC) and...

At the 2023 ASCO GU Cancers...

03/03/2023

Journal of Clinical Pathways

News

Higher Health Care Resource Utilization, Rates of Mortality and Economic Burdens in Recurrence of Renal Cell Carcinoma

10/25/2022

Yvette C. Terrie , BS Pharm, RPh;

Renal cell carcinoma (RCC) recurrence is correlated with a significant increase in mortality, health care resource utilization (HRU), and health care costs, emphasizing the substantial unmet need in patients with intermediate high-risk and...

Renal cell carcinoma (RCC)...

10/25/2022

Journal of Clinical Pathways

News

Personalizing First-Line Treatments for Metastatic Renal Cell Carcinoma

07/12/2022

Ellen Kurek ;

Researchers detail current first-line treatment options for the management of metastatic renal cell carcinoma and propose a framework for optimal treatment selection.

Researchers detail current...

07/12/2022

Journal of Clinical Pathways

News

Preoperative Short-Term Radiotherapy Followed by Chemotherapy vs Standard Schedule of Long-Term Chemoradiotherapy for the Treatment of Locally Advanced Rectal Cancer

05/31/2022

Ellen Kurek ;

Short-term radiotherapy with preoperative chemotherapy followed by surgery may be efficacious with acceptable toxicity and could be used as an alternative to chemoradiotherapy among patients with locally advanced rectal cancer.

Short-term radiotherapy with...

05/31/2022

Journal of Clinical Pathways

Current Issue

October 2024

Volume 10

Issue 5

Current Issue

Issue Archive

Special Reports

Sponsored

JCP Special Report

The Value of Tissue-Based Genomic Profiling in Oncology

09/17/2024

Innovations in precision oncology have helped healthcare providers to create more personalized treatment plans and improve patient outcomes. View this special report to learn more.

Innovations in precision...

09/17/2024

Journal of Clinical Pathways

Sponsored

Special Report

Shedding Light on Non-Small Cell Lung Cancer & Its Impact on Patients

04/03/2023

This supplement aims to raise awareness about non-small cell lung cancer (NSCLC) and its impact on patients by providing comprehensive information to help improve early detection and appropriate care.

This supplement aims to raise...

04/03/2023

Journal of Clinical Pathways

Sponsored

JCP Special Report

Brukinsa® (Zanubrutinib) for Chronic Lymphocytic Leukemia

03/31/2023

In this product monograph, read an interview with Jeff P. Sharman, MD, as he discusses important BRUKINSA® trial data including efficacy, safety, dosing, administration, and other relevant data. These key findings supported the Food and Drug...

In this product monograph, read...

03/31/2023

Journal of Clinical Pathways

Sponsored

JCP Special Report

Tumor Lysis Syndrome: Early Diagnosis and Management

01/04/2023

This review summarizes the diagnosis, pathophysiology, and evidence-based guidelines for the prevention and management of tumor lysis syndrome, a common, acute, life-threatening disease primarily in patients with hematologic cancers and solid...

This review summarizes the...

01/04/2023

Journal of Clinical Pathways

Sponsored

JCP Special Report

A Tumor Lysis Syndrome Risk Assessment and Its Impact on Patients

08/09/2022

In an interview with Journal of Clinical Pathways, Nicholas Short, MD, shares objectives on the design and benefits of MD Anderson’s Tumor Lysis Syndrome clinical assessment for patient risk and impact on patient care.

In an interview with Journal of...

08/09/2022

Journal of Clinical Pathways

Updated NCCN Guidelines on B-Cell Lymphomas

Sponsored

JCP Special Report

Overview of the Updated NCCN Guidelines on B-Cell Lymphomas

06/15/2022

Robert Fee ;

Updated multiple times in 2022, the National Comprehensive Cancer Network (NCCN) Guidelines for B-Cell Lymphomas provide recommendations for the prevention, diagnosis, and management of malignancies.

Updated multiple times in 2022,...

06/15/2022

Journal of Clinical Pathways

Sponsored

Special Report

Expanded Indication for Zanubrutinib: Marginal Zone Lymphoma and Waldenström’s Macroglobulinemia

06/10/2022

In an interview with Journal of Clinical Pathways, Mitul Gandhi, MD, reviews the clinical impact and treatment approaches and challenges for patients with marginal zone lymphoma and Waldenström’s macroglobulinemia.

In an interview with Journal of...

06/10/2022

Journal of Clinical Pathways

JCP Special Report

Recommendations for Creating an Oncology Clinical Pathways Framework Tool Based on Payer, Provider, and Patient Priorities: Findings From the 2021 Care Pathways Working Group

05/20/2022

Robin T. Zon , MD, FACP, FASCO;

Gordon Kuntz ;

Winston Wong , PharmD;

The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...

The Journal of Clinical Pathways...

05/20/2022

Journal of Clinical Pathways

Overview of the Updated NCCN Guidelines on Triple-Negative Breast Cancer

Sponsored

Special Report

Overview of the Updated NCCN Guidelines on Triple-Negative Breast Cancer

12/15/2021

Deborah Abrams Kaplan ;

NCCN released updates to its practice guidelines on treating triple-negative breast cancer, featuring updates on sacituzumab govitecan recommendations and more.

NCCN released updates to its...

12/15/2021

Journal of Clinical Pathways

Sponsored

Special Report

Navigating the Patient Journey for Unresectable Stage III Non-Small Cell Lung Cancer

09/16/2021

.ryan-test { display: none; } .body-content h3 { font-size: 18px; line-height: 18px; color: #000000; font-weight: 600px; } .related-content { display: none; } .body-content div > div:nth-of-type(3) .paragraph > h3 >...

.ryan-test { display:...

09/16/2021

Journal of Clinical Pathways

Journal of Clinical Pathways Newsletter

Genitourinary Cancer News

Current Issue

Special Reports

Subscribe

Specialties

Events

Year Round Education

HMP Global Products